Tickers: XTSX:VM, PINX:VYYRF
CALGARY, Alberta - TheNewswire - January 10th, 2020, Voyageur Pharmaceuticals Ltd. (TSXV:VM) (the "Company" or "Voyageur") is pleased to announce the formulation and registration submission of Natural and Non Prescription Drug (NNHP) applications to Health Canada's for one additional radiographic product named MultiXthin.
MultiXthin is a specially formulated, low density, pre-mixed barium suspension product. It will be sold in a 2-liter container and is for multiple testing applications. Barium sulfate suspension is for oral consumption to aid in radiographic x-ray procedures to view the upper gastrointestinal tract (esophagus, stomach, duodenum). MultiXthin is similar in composition to the dry powdered MultiXba. However, the barite has been pre-mixed in solution with 60% barium and is designed to provide ultra-fine particle distribution for superior coating of the GI Trac.
Voyageur is continuing to develop multiple products and is currently developing its iopamidol-based Iodine contrast named IoX. The IoX product line is the focus in the near term for submission to Health Canada .
Voyageur Pharmaceuticals Ltd. is a Canadian public company listed on the TSX Venture Exchange under the trading symbol VM. Voyageur is focused on the development of Active Pharmaceutical Ingredients (API) minerals. The current focus is developing barite and Iodine radiocontrast products and developing bromine-based pharmaceutical products.
Voyageur's goal is to generate positive cash flow from operations through its signed joint venture with Chief Medical Supply Ltd. - Alberta's only pharmaceutical manufacturer. The joint venture contemplates turnkey manufacturing, bottling and distribution of barium radiopharmaceuticals for MRI, X-ray and CT scan applications. The Company also contemplates similar Health Canada registration applications for iodine and bromine products also for medical applications. Voyageur owns 100% interest in three barium sulfate ("Barite") deposits including two properties suitable in grade for the industrial barite market place, as well as a significant interests in a high-grade iodine, lithium & bromine brine project in Utah, USA.
About ImagingX Pharmaceuticals
Voyageur formed ImagingX, a gross revenue-sharing joint venture company with Chief Medical Supply Ltd (CMS). CMS provides high quality, competitively priced pharmaceuticals and hemodialysis products to pharmacies and hospitals in Canada. Operating from both its 81,000 square-foot plant in Calgary, Alberta and its 163,000 square-foot facility in Mississauga, Ontario, CMS can supply products coast-to-coast. Regulated by Health Canada and complying with the Canadian Food and Drug Act, CMS has both drug and medical device establishment licenses issued by Health Canada. CMS currently has the combined bottling capacity of 760,000 bottles per day and has a turnkey sterile bottle line ready for ImagingX iodine contrast production.
ImagingX is employing a strategy of selling competitively priced radiopharmaceuticals for MRI, X-ray and CT scan applications. The main focus to date has been on barium, with the inclusion of iodine in 2020. The joint venture obligates Voyageur to provide the Active Pharmaceutical Ingredient minerals for the products and CMS to manufacture the products. The partners each split gross revenue 50/50. This joint venture relationship is designed for ImagingX to be highly competitive by controlling all input costs under the motto of:
"From the Earth to the Bottle"
For further information, please contact:
Steven R. Livingston
Mobile + (403) 471-1659
Office: + (587)-779-6166 Dial #1
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.
Cautionary Note Regarding Forward-Looking Statements:
This news release contains certain statements or disclosures relating to the Company that are based on the expectations of its management as well as assumptions made by and information currently available to the Company which may constitute forward-looking statements or information ("forward-looking statements") under applicable securities laws. All such statements and disclosures, other than those of historical fact, which address activities, events, outcomes, results or developments that the Company anticipates may or will occur in the future (in whole or in part) should be considered forward-looking statement and undue reliance should not be placed on any such statements. In some cases, forward-looking statements can be identified by the use of the words "will", "intends", "believes", "expects", forecasts", "anticipates", "plans" and similar expressions.
In particular, but without limiting the foregoing, this news release contains forward-looking statements pertaining to anticipated product registrations with Health Canada for various pharmaceutical products, the Company's plan to develop, produce and sell pharmaceutical products, anticipated cash flows, and Voyageur's ability to meet its obligations under the joint venture agreement with CMS..
The forward-looking statements contained in this news release are made as of the date hereof and the Company undertakes no obligations to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933 (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined in the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration is available.
Copyright (c) 2020 TheNewswire - All rights reserved.